Clinical Trial Update: A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection [Phase 2]

View source ↗

Summary

The Phase 2 trial of UB-421 in combination with optimized background antiretroviral therapy for multi-drug resistant HIV-1 infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Multi-drug Resistant Hiv-1 Infection

Drugs mentioned

• UB-421 (anti-CD4 antibody)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection | Phase 2 | Status: WITHDRAWN